866-997-4948(US-Canada Toll Free)

Global Market Study on Malignant Mesothelioma: Cisplatin and Combination Segment Projected to be the Second Most Lucrative Segment by Drug Type

Published By :

Persistence Market Research

Published Date : Jul 2017

Category :

Healthcare

No. of Pages : 223 Pages

An introduction to the report

All the information pertaining to the market of this rare form of cancer is provided in our recently published report“Malignant Mesothelioma Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025).” Caused due to the exposure to toxic asbestos, the occurrence of this cancer is higher in countries such as Russia and China. These two countries are pegged to represent the most lucrative markets, owing to the relatively high production of asbestos in these countries. Besides, a high consumption of asbestos in the APAC region is expected to create a sizeable opportunity for key players in this market. Our analysts have observed that the rapid substitution through generics to ease availability and affordability is the key focus area in the global malignant mesothelioma market. We have observed that the application of combination therapies is gaining traction in the market across regions. Documented evidence on the adoption of combination treatments and benefits is being made available to ease patients’ journey through the treatment process. According to our analysts, there is a great need in the market to efficiently meet the requirements for the present treatment regimen. The drugs that are currently in use do not show much response rates. The malignant mesothelioma treatment market requires drugs to increase the current survival rate.

Acquisitions and collaborations are the key strategies adopted by players to develop molecules for the better treatment of malignant mesothelioma. Companies are focusing on collaborating with established research centers and other cancer drug manufacturers to develop drugs. Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of mesothelioma drugs by governments to ensure availability in hospital pharmacies and oncology centers.

We have used our in-house epidemiology data based model to estimate the global malignant mesothelioma market numbers

Weighted average selling price has been considered to estimate the market size of various drugs mentioned in the scope of the study. Price per country is captured with the local currency. The local currency figures are then converted to USD to offer forecasts in a consistent currency standard. We have also considered the latest annual exchange rate to reflect the impact of the most recent economic conditions. Prices considered in the models are standardized based on the average dosage used per malignant mesothelioma treatment per dosage cycle of six months. Availability of branded off-patent equivalents has been taken into consideration while calculating prices. We have adopted the bottom-up approach to forecast the malignant mesothelioma market globally. Besides this, forecasting is done using our internal proprietary model that considers different macro-economic factors, industry based demand driving factors impacting the market and the relevant forecast trends apart from disease related factors.

Market Taxonomy

Drug Type

  • Pemetrexed
  • Cisplatin
  • Carboplatin
  • Gemcitabine
  • Vinorelbine
  • Others

Route of Administration

  • Oral
  • Parenteral

Region

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Oncology Centers

Research Methodology

Our research methodology leverages both primary and secondary research to collect the relevant market data. We have analyzed the global malignant mesothelioma market by considering key player revenue, usage patterns, historic trends, and problems faced by oncologists, the required treatment developments, and most preferred drugs. Key opinion leaders including experienced healthcare professionals in various healthcare facilities at the country level have been considered for primary research. These estimates have been further validated with drug manufacturers, distributors, and suppliers. Extensive secondary research has been carried out to understand the epidemiology of malignant mesothelioma, treatment rate, adoption rate, regulatory scenarios, average selling price and the global reimbursement scenario by referring to published scientific literature from various databases such as the WHO, Asbestos.com, PubMed, Springer, and Wiley among many others. We have also analyzed the various companies’ annual reports, investor presentations, SEC filings, reports and press releases to fetch substantial information pertaining to the market size, trends, opportunities, drivers, and restraints.

1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune

2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy

3. Malignant Mesothelioma Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Demand and Supply side Driver
3.3. Global Trend
3.4. Pipeline Snapshot
3.5. Medicines in Development for Malignant Mesothelioma, 2016
3.6. Asbestos Production By Country
3.7. Asbestos Consumption By Country
3.8. Epidemiology Data

4. North America Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025
4.1. Introduction
4.2. Key Regulations
4.3. Regional Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Trends
4.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
4.4.1. U.S.
4.4.2. Canada
4.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
4.5.1. U.S.
4.5.2. Canada
4.6. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012–2016
4.6.1. Premetrexed and combination
4.6.2. Cisplatin and combination
4.6.3. Carboplatin and combination
4.6.4. Gemcitabine and combination
4.6.5. Vinorelbine and combination
4.6.6. Others combinations
4.7. Market Size (US$ Mn) Forecast By Drug Class, 2017–2025
4.7.1. Premetrexed and combination
4.7.2. Cisplatin and combination
4.7.3. Carboplatin and combination
4.7.4. Gemcitabine and combination
4.7.5. Vinorelbine and combination
4.7.6. Others combinations
4.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
4.8.1. Oral
4.8.2. Parenteral
4.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
4.9.1. Oral
4.9.2. Parenteral
4.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
4.10.1. Hospital Pharmacies
4.10.2. Retail Pharmacies
4.10.3. Oncology Centers
4.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2025
4.11.1. Hospital Pharmacies
4.11.2. Retail Pharmacies
4.11.3. Oncology Centers
4.12. Drivers and Restraints: Impact Analysis
4.13. Market Attractiveness Analysis
4.13.1. By Country
4.13.2. By Drug Class
4.13.3. By Route of Administration
4.13.4. By Distribution Channel

5. Latin America Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025
5.1. Introduction
5.2. Key Regulations
5.3. Regional Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
5.4.1. Brazil
5.4.2. Mexico
5.4.3. Rest of Latin America
5.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
5.5.1. Brazil
5.5.2. Mexico
5.5.3. Rest of Latin America
5.6. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012–2016
5.6.1. Premetrexed and combination
5.6.2. Cisplatin and combination
5.6.3. Carboplatin and combination
5.6.4. Gemcitabine and combination
5.6.5. Vinorelbine and combination
5.6.6. Others combinations
5.7. Market Size (US$ Mn) Forecast By Drug Class, 2017–2025
5.7.1. Premetrexed and combination
5.7.2. Cisplatin and combination
5.7.3. Carboplatin and combination
5.7.4. Gemcitabine and combination
5.7.5. Vinorelbine and combination
5.7.6. Others combinations
5.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
5.8.1. Oral
5.8.2. Parenteral
5.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
5.9.1. Oral
5.9.2. Parenteral
5.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
5.10.1. Hospital Pharmacies
5.10.2. Retail Pharmacies
5.10.3. Oncology Centers
5.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2025
5.11.1. Hospital Pharmacies
5.11.2. Retail Pharmacies
5.11.3. Oncology Centers
5.12. Drivers and Restraints: Impact Analysis
5.13. Market Attractiveness Analysis
5.13.1. By Country
5.13.2. By Drug Class
5.13.3. By Route of Administration
5.13.4. By Distribution Channel

6. Europe Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025
6.1. Introduction
6.2. Key Regulations
6.3. Regional Market Dynamics
6.3.1. Drivers
6.3.2. Restraints
6.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
6.4.1. Germany
6.4.2. U.K.
6.4.3. France
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Rest of Europe
6.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
6.5.1. Germany
6.5.2. U.K.
6.5.3. France
6.5.4. Italy
6.5.5. Spain
6.5.6. Russia
6.5.7. Rest of Europe
6.6. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012–2016
6.6.1. Premetrexed and combination
6.6.2. Cisplatin and combination
6.6.3. Carboplatin and combination
6.6.4. Gemcitabine and combination
6.6.5. Vinorelbine and combination
6.6.6. Others combinations
6.7. Market Size (US$ Mn) Forecast By Drug Class, 2017–2025
6.7.1. Premetrexed and combination
6.7.2. Cisplatin and combination
6.7.3. Carboplatin and combination
6.7.4. Gemcitabine and combination
6.7.5. Vinorelbine and combination
6.7.6. Others combinations
6.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
6.8.1. Oral
6.8.2. Parenteral
6.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
6.9.1. Oral
6.9.2. Parenteral
6.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
6.10.1. Hospital Pharmacies
6.10.2. Retail Pharmacies
6.10.3. Oncology Centers
6.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2025
6.11.1. Hospital Pharmacies
6.11.2. Retail Pharmacies
6.11.3. Oncology Centers
6.12. Drivers and Restraints: Impact Analysis
6.13. Market Attractiveness Analysis
6.13.1. By Country
6.13.2. By Drug Class
6.13.3. By Route of Administration
6.13.4. By Distribution Channel

7. Asia Pacific Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025
7.1. Introduction
7.2. Key Regulations
7.3. Regional Market Dynamics
7.3.1. Drivers
7.3.2. Restraints
7.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
7.4.1. China
7.4.2. Japan
7.4.3. India
7.4.4. ASEAN
7.4.5. Australia and New Zealand
7.4.6. Rest of Asia Pacific
7.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
7.5.1. China
7.5.2. Japan
7.5.3. India
7.5.4. ASEAN
7.5.5. Australia and New Zealand
7.5.6. Rest of Asia Pacific
7.6. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012–2016
7.6.1. Premetrexed and combination
7.6.2. Cisplatin and combination
7.6.3. Carboplatin and combination
7.6.4. Gemcitabine and combination
7.6.5. Vinorelbine and combination
7.6.6. Others combinations
7.7. Market Size (US$ Mn) Forecast By Drug Class, 2017–2025
7.7.1. Premetrexed and combination
7.7.2. Cisplatin and combination
7.7.3. Carboplatin and combination
7.7.4. Gemcitabine and combination
7.7.5. Vinorelbine and combination
7.7.6. Others combinations
7.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
7.8.1. Oral
7.8.2. Parenteral
7.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
7.9.1. Oral
7.9.2. Parenteral
7.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
7.10.1. Hospital Pharmacies
7.10.2. Retail Pharmacies
7.10.3. Oncology Centers
7.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2025
7.11.1. Hospital Pharmacies
7.11.2. Retail Pharmacies
7.11.3. Oncology Centers
7.12. Drivers and Restraints: Impact Analysis
7.13. Market Attractiveness Analysis
7.13.1. By Country
7.13.2. By Drug Class
7.13.3. By Route of Administration
7.13.4. By Distribution Channel

8. Middle East & Africa Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025
8.1. Introduction
8.2. Key Regulations
8.3. Regional Market Dynamics
8.3.1. Drivers
8.3.2. Restraints
8.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
8.4.1. GCC Countries
8.4.2. South Africa
8.4.3. North Africa
8.4.4. Rest of MEA
8.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. North Africa
8.5.4. Rest of MEA
8.6. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012–2016
8.6.1. Premetrexed and combination
8.6.2. Cisplatin and combination
8.6.3. Carboplatin and combination
8.6.4. Gemcitabine and combination
8.6.5. Vinorelbine and combination
8.6.6. Others combinations
8.7. Market Size (US$ Mn) Forecast By Drug Class, 2017–2025
8.7.1. Premetrexed and combination
8.7.2. Cisplatin and combination
8.7.3. Carboplatin and combination
8.7.4. Gemcitabine and combination
8.7.5. Vinorelbine and combination
8.7.6. Others combinations
8.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
8.8.1. Oral
8.8.2. Parenteral
8.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
8.9.1. Oral
8.9.2. Parenteral
8.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
8.10.1. Hospital Pharmacies
8.10.2. Retail Pharmacies
8.10.3. Oncology Centers
8.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2025
8.11.1. Hospital Pharmacies
8.11.2. Retail Pharmacies
8.11.3. Oncology Centers
8.12. Drivers and Restraints: Impact Analysis
8.13. Market Attractiveness Analysis
8.13.1. By Country
8.13.2. By Drug Class
8.13.3. By Route of Administration
8.13.4. By Distribution Channel

9. Competition Landscape
9.1. Competition Dashboard
9.2. Company Profiles (Details – Overview, Financials, Strategy, SWOT, Recent Developments)
9.2.1. AstraZeneca Plc.
9.2.2. Bristol-Myers Squibb Company
9.2.3. F. Hoffmann-La Roche Ltd.
9.2.4. Merck & Co., Inc.
9.2.5. Novartis AG
9.2.6. Pfizer Inc.
9.2.7. Sanofi
9.2.8. Eli Lilly and Company
9.2.9. Teva Pharmaceuticals
9.2.10. Boehringer Ingelheim GmbH
9.2.11. Mylan N.V.
9.2.12. Fresenius Kabi AG
9.2.13. Sun Pharmaceuticals Industries Ltd
9.2.14. Corden Pharma International GmbH
9.2.15. Concordia International Corp
9.2.16. Kyowa Hakko Kirin Co Ltd.
9.2.17. Polaris Pharmaceuticals, Inc.
9.2.18. MolMed SpA
9.2.19. Ono Pharmaceutical Co. Ltd
9.2.20. Nichi-Iko Pharmaceutical Co., Ltd

10. Global Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025, By Region
10.1. Historical Market Size (US$ Mn) Analysis By Region, 2012–2016
10.1.1. North America
10.1.2. Latin America
10.1.3. Europe
10.1.4. Asia Pacific
10.1.5. Middle East & Africa
10.2. Market Size (US$ Mn) By Region, 2017–2025
10.2.1. North America
10.2.2. Latin America
10.2.3. Europe
10.2.4. Asia Pacific
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis By Region

11. Global Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025, By Drug Class
11.1. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012–2016
11.1.1. Premetrexed and combination
11.1.2. Cisplatin and combination
11.1.3. Carboplatin and combination
11.1.4. Gemcitabine and combination
11.1.5. Vinorelbine and combination
11.1.6. Others combinations
11.2. Market Size (US$ Mn) and Forecast By Drug Class, 2017–2025
11.2.1. Premetrexed and combination
11.2.2. Cisplatin and combination
11.2.3. Carboplatin and combination
11.2.4. Gemcitabine and combination
11.2.5. Vinorelbine and combination
11.2.6. Others combinations
11.3. Market Attractiveness Analysis By Drug Class

12. Global Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025, By Route of Administration
12.1. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
12.1.1. Oral
12.1.2. Parenteral
12.2. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
12.2.1. Oral
12.2.2. Parenteral
12.3. Market Attractiveness Analysis By Route of Administration

13. Global Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025, By Distribution Channel
13.1. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
13.1.1. Hospital Pharmacies
13.1.2. Retail Pharmacies
13.1.3. Oncology Centers
13.2. Market Size (US$ Mn) By Distribution Channel, 2017–2025
13.2.1. Hospital Pharmacies
13.2.2. Retail Pharmacies
13.2.3. Oncology Centers
13.3. Market Attractiveness Analysis By Distribution Channel

14. Global Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025
14.1. Market Size and Y-o-Y Growth

List of Table

Table 1: Pipeline Products (Phase I)
Table 2: Pipeline Products (Phase 1|Phase 2 and phase 2)
Table 3: Pipeline Products (Phase 2)
Table 4: Pipeline Products (Phase 2 and Phase 2|Phase 3) 
Table 5: Pipeline Products ( Phase 3|4)
Table 6: List of orphan drugs in the pipeline for malignant mesothelioma
Table 7: Asbestos fiber Production (In Tonnes) 2011-2013
Table 8: Asbestos fiber consumption (In Tonnes) 2011-2013
Table 9: Epidemiology data of Malignant Mesothelioma 2015
Table 10: Reimbursement 
Table 11: North America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 12: North America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
Table 13: North America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Route of Administration
Table 14: North America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel
Table 15: Latin America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 16: Latin America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
Table 17: Latin America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Route of Administration
Table 18: Latin America Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel
Table 19: Europe Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 20: Europe Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
Table 21: Europe Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Route of Administration
Table 22: Europe Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel
Table 23: APAC Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 24: APAC Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
Table 25: APAC Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Route of Administration
Table 26: APAC Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel
Table 27: MEA Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 28: MEA Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
Table 29: MEA Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Route of Administration
Table 30: MEA Malignant Mesothelioma Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel
Table 31: Global Malignant Mesothelioma Market Size (US$ Mn) 2012–2016 and Forecast 2017-2025 By Region, 
Table 32: Global Malignant Mesothelioma Market Size (US$ Mn) 2012–2016 and Forecast 2017-2025 By Drug Type, 
Table 33: Global Malignant Mesothelioma Market Size (US$ Mn) 2012–2016 and Forecast 2017-2025 By Route of Administration, 
Table 34: Global Malignant Mesothelioma Market Size (US$ Mn) 2012–2016 and Forecast 2017-2025 By Distribution Channel,

List of Chart

Figure 1: North America Malignant Mesothelioma Market Value Share By Route of Administration (2017)
Figure 2: North America Malignant Mesothelioma Market Value Share By Drug type (2017)
Figure 3: North America Malignant Mesothelioma Market Value Share By Distribution Channel (2017)
Figure 4: North America Malignant Mesothelioma Market Size Analysis, 2012–2016
Figure 5: North America Malignant Mesothelioma Market Size Analysis, 2017–2025
Figure 6: North America Malignant Mesothelioma Market Share Analysis (%) By Country, 2017 & 2025 
Figure 7: North America Malignant Mesothelioma Market Y-o-Y Growth (%) By Country, 2016–2025
Figure 8: U.S. Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 9: U.S. Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 10: Canada Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 11: Canada Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 12: North America Malignant Mesothelioma Market Attractiveness Analysis, By Country
Figure 13: North America Malignant Mesothelioma Market Attractiveness Analysis, By Drug Type
Figure 14: North America Malignant Mesothelioma Market Attractiveness Analysis, By Route of Administration
Figure 15: North America Malignant Mesothelioma Market Attractiveness Analysis, By Distribution Channel
Figure 16: Latin America Malignant Mesothelioma Market Value Share By Route of Administration (2017)
Figure 17:  Latin America Malignant Mesothelioma Market Value Share By Drug type (2017)
Figure 18: Latin America Malignant Mesothelioma Market Value Share By Distribution Channel (2017)
Figure 19: Latin America Malignant Mesothelioma Market Size Analysis, 2012–2016
Figure 20: Latin America Malignant Mesothelioma Market Size Analysis, 2017–2025
Figure 21: Latin America Malignant Mesothelioma Market Share Analysis (%) By Country, 2017 & 2025 
Figure 22: Latin America Malignant Mesothelioma Market Y-o-Y Growth (%) By Country, 2016–2025
Figure 23: Brazil Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 24: Brazil Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 25: Mexico Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 26: Mexico Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 27: Rest of Latin America Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 28: Latin America Malignant Mesothelioma Market Attractiveness Analysis, By Country
Figure 29: Latin America Malignant Mesothelioma Market Attractiveness Analysis, By Drug Type
Figure 30: Latin America Malignant Mesothelioma Market Attractiveness Analysis, By Route of Administration
Figure 31: Latin America Malignant Mesothelioma Market Attractiveness Analysis, By Distribution Channel
Figure 32: Europe Malignant Mesothelioma Market Value Share By Route of Administration (2017)
Figure 33: Europe Malignant Mesothelioma Market Value Share By Drug type (2017)
Figure 34: Europe Malignant Mesothelioma Market Value Share By Distribution Channel (2017)
Figure 35: Europe Malignant Mesothelioma Market Size Analysis, 2012–2016
Figure 36: Europe Malignant Mesothelioma Market Size Analysis, 2017–2025
Figure 37: Europe Malignant Mesothelioma Market Share Analysis (%) By Country, 2017 & 2025 
Figure 38: Europe Malignant Mesothelioma Market Y-o-Y Growth (%) By Country, 2016–2025
Figure 39: Germany Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 40: Germany Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 41: France Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 42: France Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 43: U.K. Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 44: U.K. Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 45: Spain Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 46: Spain Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 47: Italy Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 48: Italy Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 49: Russia Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 50: Russia Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 51: Rest of Europe Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 52: Rest of Europe Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 53: Europe Malignant Mesothelioma Market Attractiveness Analysis, By Country
Figure 54: Europe Malignant Mesothelioma Market Attractiveness Analysis, By Drug Type
Figure 55: Europe Malignant Mesothelioma Market Attractiveness Analysis, By Route of Administration
Figure 56: Europe Malignant Mesothelioma Market Attractiveness Analysis, By Distribution Channel
Figure 57: Asia-Pacific Malignant Mesothelioma Market Value Share By Route of Administration (2017)
Figure 58: Asia-Pacific Malignant Mesothelioma Market Value Share By Drug type (2017)
Figure 59: Asia-Pacific Malignant Mesothelioma Market Value Share By Distribution Channel (2017)
Figure 60: Asia-Pacific Malignant Mesothelioma Market Size Analysis, 2012–2016
Figure 61: Asia-Pacific Malignant Mesothelioma Market Size Analysis, 2017–2025
Figure 62: APAC Malignant Mesothelioma Market Share Analysis (%) By Country, 2017 & 2025 
Figure 63: APAC Malignant Mesothelioma Market Y-o-Y Growth (%) By Country, 2016–2025
Figure 64: Japan Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 65: Japan Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 66: ANZ Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 67: ANZ Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 68: China Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 69: China Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 70: India Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 71: India Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 72: Rest of APAC Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 73: Rest of APAC Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 74: APAC Malignant Mesothelioma Market Attractiveness Analysis, By Country
Figure 75: APAC Malignant Mesothelioma Market Attractiveness Analysis, By Drug Type
Figure 76: APAC Malignant Mesothelioma Market Attractiveness Analysis, By Route of Administration
Figure 77: APAC Malignant Mesothelioma Market Attractiveness Analysis, By Distribution Channel
Figure 78: MEA Malignant Mesothelioma Market Value Share By Route of Administration (2017)
Figure 79: MEA Malignant Mesothelioma Market Value Share By Drug type (2017)
Figure 80: MEA Malignant Mesothelioma Market Value Share By Distribution Channel (2017)
Figure 81: MEA Malignant Mesothelioma Market Size Analysis, 2012–2016
Figure 82: MEA Malignant Mesothelioma Market Size Analysis, 2017–2025
Figure 83: MEA Malignant Mesothelioma Market Share Analysis (%) By Country, 2017 & 2025 
Figure 84: MEA Malignant Mesothelioma Market Y-o-Y Growth (%) By Country, 2016–2025
Figure 85: GCC Countries Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 86: GCC Countries Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 87: South Africa Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 88: South Africa Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 89: Rest of MEA Malignant Mesothelioma Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 90: Rest of MEA Malignant Mesothelioma Market Absolute $ Opportunity, 2017–2025
Figure 91: MEA Malignant Mesothelioma Market Attractiveness Analysis, By Country
Figure 92: MEA Malignant Mesothelioma Market Attractiveness Analysis, By Drug Type
Figure 93: MEA Malignant Mesothelioma Market Attractiveness Analysis, By Route of Administration
Figure 94: MEA Malignant Mesothelioma Market Attractiveness Analysis, By Distribution Channel
Figure 95: Global Malignant Mesothelioma Market Share Analysis (%) By Country, 2017 & 2025
Figure 96: Global Malignant Mesothelioma Market Y-o-Y Growth (%) By Country, 2016–2025
Figure 97: Global Malignant Mesothelioma Market Attractiveness Analysis By Region, 2017–2025
Figure 98: Global Malignant Mesothelioma Market Share Analysis (%) By Drug Type, 2017 & 2025
Figure 99: Global Malignant Mesothelioma Market Y-o-Y Growth (%) By Drug Type, 2016–2025
Figure 100: Global Malignant Mesothelioma Market Attractiveness Analysis By Drug Type, 2017–2025
Figure 101: Global Malignant Mesothelioma Market Share Analysis (%) By route of administration, 2017 & 2025
Figure 102: Global Malignant Mesothelioma Market Y-o-Y Growth (%) By route of administration, 2016–2025
Figure 103: Global Malignant Mesothelioma Market Attractiveness Analysis By route of administration, 2017–2025
Figure 104: Global Malignant Mesothelioma Market Share Analysis (%) By Distribution Channel, 2017 & 2025
Figure 105: Global Malignant Mesothelioma Market Y-o-Y Growth (%) By Distribution Channel, 2016–2025
Figure 106: Global Malignant Mesothelioma Market Attractiveness Analysis By Distribution Channel, 2017–2025
Figure 107: Global Malignant Mesothelioma Market Value Analysis and Forecast, 2016–2025 (US$ Mn)
Figure 108: Global Malignant Mesothelioma Market Absolute $ Opportunity (US$ Mn), 2012–2016
Figure 109: Global Malignant Mesothelioma Market Absolute $ Opportunity (US$ Mn), 2016–2025

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *